Drug Trial Radar · NCT06757894
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Feb 1, 2028
Study completion Feb 1, 2034
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gansu Cancer Hospital; Ganzhou Cancer Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital of Guangzhou Medical University
- First posted
- Jan 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.
Conditions
- Follicular Lymphoma (FL)
Interventions
ZuberitamabDrug
375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)
BendamustineDrug
90 mg/m², administered on D1-2 of C1-C6
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response (CR)Time frame: Up to 6 cycles (each cycle is 28 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.